These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39017930)

  • 1. Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.
    Fernbach S; Mair NK; Abela IA; Groen K; Kuratli R; Lork M; Thorball CW; Bernasconi E; Filippidis P; Leuzinger K; Notter J; Rauch A; Hirsch HH; Huber M; Günthard HF; Fellay J; Kouyos RD; Hale BG;
    J Exp Med; 2024 Sep; 221(9):. PubMed ID: 39017930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
    Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
    Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
    J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An easy assay to detect autoantibodies neutralizing cytokines in subjects with critical infections.
    Donadel N; Tesser A; Valencic E; De Martino E; Boz V; Pin A; Zorat F; Pozzato G; Tommasini A
    J Immunol Methods; 2024 Jul; 530():113696. PubMed ID: 38797274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies neutralizing type I IFNs are present in
    Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs C; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari NS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Ostrowski SR; Condino-Neto A; Prando C; Bonradenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Vandreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Duval X; Mentré F; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Cobat A; Abel L; Casanova JL
    Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34413139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
    PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
    Xu W; Wen X; Cong X; Jiang W
    J Med Virol; 2023 Oct; 95(10):e29137. PubMed ID: 37792386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
    Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Mégarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A
    Proc Natl Acad Sci U S A; 2022 May; 119(21):e2200413119. PubMed ID: 35576468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
    Meager A; Visvalingam K; Peterson P; Möll K; Murumägi A; Krohn K; Eskelin P; Perheentupa J; Husebye E; Kadota Y; Willcox N
    PLoS Med; 2006 Jul; 3(7):e289. PubMed ID: 16784312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
    de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
    J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
    Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
    J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
    Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
    J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection.
    Chen LF; Yang CD; Cheng XB
    Front Immunol; 2021; 12():788368. PubMed ID: 35003106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
    Abers MS; Rosen LB; Delmonte OM; Shaw E; Bastard P; Imberti L; Quaresima V; Biondi A; Bonfanti P; Castagnoli R; Casanova JL; Su HC; Notarangelo LD; Holland SM; Lionakis MS
    Immunol Cell Biol; 2021 Oct; 99(9):917-921. PubMed ID: 34309902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains.
    Yasamut U; Thongkum W; Moonmuang S; Sakkhachornphop S; Chaiwarith R; Praparattanapan J; Wipasa J; Chawansuntati K; Supparatpinyo K; Lai E; Tayapiwatana C
    Front Immunol; 2019; 10():1905. PubMed ID: 31474987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.
    Scordio M; Frasca F; Santinelli L; Sorrentino L; Pierangeli A; Turriziani O; Mastroianni CM; Antonelli G; Viscidi RP; d'Ettorre G; Scagnolari C
    Clin Immunol; 2022 Aug; 241():109068. PubMed ID: 35764258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
    Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
    Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
    Shi D; Chen J; Zhao M; Tang Y; Zhao C; Jin Y; Tian D; Liao Y; Wang X; Wang W; Fan X; Yi Z; Chen X; Ling Y
    J Clin Immunol; 2024 Mar; 44(3):80. PubMed ID: 38462559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.